Lea Witkowsky, PhD, is a molecular biologist by training and executive director of the Kavli Center for Ethics, Science, and the Public at the University of California, Berkeley, where she leads initiatives that connect scientists, humanities scholars, policymakers and the public to examine the ethical and societal dimensions of emerging science and technology. The center focuses on fostering public-responsive and ethically grounded approaches to advances in artificial intelligence, neuroscience and genome editing. ACORD, the Autism Communities and Research Dialogue initiative, reflects the center’s commitment to public-responsive neuroscience by creating space for basic scientists alongside autistic and autism community members to shape research questions, priorities and impacts together.
Lea Witkowsky
Executive director
Kavli Center for Ethics, Science, and the Public, University of California, Berkeley
From this contributor
How basic neuroscientists can connect with autistic people and their communities
A first-of-its-kind workshop offers a template for autism researchers who want to incorporate community perspectives into their work.
How basic neuroscientists can connect with autistic people and their communities
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.